Apexigen (APGNW) Stock

Profile

Full Name:

Apexigen, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

22 February 2021

Indexes:

Not included

Description:

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with APGNW included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of Apexigen?
  • What is the ticker symbol for Apexigen?
  • Does Apexigen pay dividends?
  • What sector is Apexigen in?
  • What industry is Apexigen in?
  • What country is Apexigen based in?
  • When did Apexigen go public?
  • Is Apexigen in the S&P 500?
  • Is Apexigen in the NASDAQ 100?
  • Is Apexigen in the Dow Jones?
  • When does Apexigen report earnings?

What is the primary business of Apexigen?

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

What is the ticker symbol for Apexigen?

The ticker symbol for Apexigen is NASDAQ:APGNW

Does Apexigen pay dividends?

No, Apexigen does not pay dividends

What sector is Apexigen in?

Apexigen is in the Healthcare sector

What industry is Apexigen in?

Apexigen is in the Biotechnology industry

What country is Apexigen based in?

Apexigen is headquartered in United States

When did Apexigen go public?

Apexigen's initial public offering (IPO) was on 22 February 2021

Is Apexigen in the S&P 500?

No, Apexigen is not included in the S&P 500 index

Is Apexigen in the NASDAQ 100?

No, Apexigen is not included in the NASDAQ 100 index

Is Apexigen in the Dow Jones?

No, Apexigen is not included in the Dow Jones index

When does Apexigen report earnings?

The date for Apexigen's next earnings report has not been announced yet